Financial Ratios

KABRA DRUGS LTD.

NSE : NABSE : 524322ISIN CODE : INE323K01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE7.190 (0 %)
PREV CLOSE ( ) 7.19
OPEN PRICE ( ) 7.19
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2457
TODAY'S LOW / HIGH ( )7.19 7.19
52 WK LOW / HIGH ( ) 3.187.19
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.77-0.42-0.41-0.14-0.38
   CEPS(Rs)-0.77-0.40-0.34-0.06-0.30
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-1.67-0.90-0.47-0.060.07
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)
   EBIT Margin(%)
   Pre Tax Margin(%)
   PAT Margin (%)
   Cash Profit Margin (%)
Performance Ratios
   ROA(%)-47.15-17.39-12.78-4.11-10.36
   ROE(%)0.000.000.00-2869.33-144.20
   ROCE(%)-52.60-27.96-27.33-8.82-19.67
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.000.000.000.00
Efficiency Ratios
   Fixed Capital/Sales(x)
   Receivable days
   Inventory Days
   Payable days
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-7.23-11.380.00-48.63-1.84
   Price/Book(x)-3.34-5.080.00-49.717.71
   Yield(%)0.000.000.000.00
   EV/Net Sales(x)
   EV/Core EBITDA(x)-11.33-17.23-35.49-74.31-7.16
   EV/EBIT(x)-11.33-16.31-29.32-34.56-5.74
   EV/CE(x)5.434.143.761.430.61
   M Cap / Sales
Growth Ratio
   Net Sales Growth(%)-100.00
   Core EBITDA Growth(%)-92.57-17.83-447.4078.4687.63
   EBIT Growth(%)-82.20-2.92-208.0962.8992.52
   PAT Growth(%)-82.26-2.98-202.1163.8393.01
   EPS Growth(%)-82.26-2.98-202.0863.8293.01
Financial Stability Ratios
   Total Debt/Equity(x)-1.89-2.61-4.33-23.5420.97
   Current Ratio(x)0.470.630.850.940.94
   Quick Ratio(x)0.470.630.850.940.94
   Interest Cover(x)-1088.65-1698.31-50.52-21.58
   Total Debt/Mcap(x)0.570.510.472.72

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.